Cardio Diagnostics Holdings

Cardio Diagnostics Holdings is on a mission to combat cardiovascular disease through its innovative, AI-integrated epigenetic-genetic testing platform. The company has achieved key milestones with the commercial launch of its Epi+Gen CHD™ risk assessment test and the development of its PrecisionCHD™ diagnostic aid. Its strategy centers on securing broader insurance reimbursement, pursuing regulatory clearances to expand test utility, and establishing strategic partnerships to integrate its technology into large healthcare systems. As a micro-cap public company, it is in a critical commercial and validation stage, aiming to demonstrate clinical utility and drive adoption.

An integrated platform combining epigenetic (DNA methylation) analysis, genetic variant analysis, and proprietary artificial intelligence/machine learning algorithms to generate personalized risk scores and diagnostic aids for cardiovascular disease.

Faces competition from traditional risk calculators (zero cost), advanced lipid/biomarker tests, and static genetic risk scores. Its key differentiator is the integration of dynamic epigenetics with genetics via AI, a niche with few direct competitors but one that requires robust validation to overcome clinical inertia.